Takayuki Yoshino

NECTIN4 defines a subtype-dependent tumor state coupling enfortumab vedotin targetability to antitumor immunity in bladder cancer

The paper identifies NECTIN4 as a subtype-dependent determinant of tumor state and antitumor immunity in bladder cancer, linking its expression to response to enfortumab vedotin and checkpoint inhibitors.

Catalog of gut microbiota alterations associated with anticancer therapies across multiple cancer types

The paper analyzes gut microbiota changes across 264 cancer patients treated with 22 anticancer drugs, finding drug-specific and treatment-related microbiota alterations.

Nutrient availability dictates cancer metabolism-based therapeutic responses of non-oncology drugs

This study introduces CM-SLP, a platform to identify non-oncology drugs that enhance cancer cell death under altered nutrient conditions by targeting metabolic vulnerabilities.

Cell competition confers anchorage plasticity of disseminated tumor cells

The paper shows cell competition enables loser cells to gain metastatic potential through anchorage plasticity, mediated by AST factors, and demonstrates this in breast cancer metastasis.

Tumour specimen cold ischemia time impacts molecular cancer drug target discovery

This study shows that cold ischemia time significantly affects molecular profiles in tumor and normal tissues, impacting drug target discovery.